newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

  • Verrica Pharmaceuticals Inc. announced acceptance of a late-breaking abstract reporting Phase 2 exploratory data for its novel oncolytic peptide VP-315 for basal cell carcinoma treatment.
  • The data will be presented at the 2026 Society for Investigative Dermatology Annual Meeting from May 13-16, 2026, in Chicago, Illinois.
  • The presentation titled "VP-315 Demonstrates Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors" will occur on Friday, May 15, 2026, from 4:30 pm to 6:00 pm in Salons B,C,D at the Hilton Chicago.
  • VP-315 (ruxotemitide) is a first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into tumors to induce immunogenic cell death & unleash tumor antigens for T cell responses.
  • Verrica holds an exclusive worldwide license to develop & commercialize VP-315 for dermatologic oncology indications including non-metastatic melanoma & non-metastatic merkel cell carcinoma, with initial focus on basal cell & squamous cell carcinomas.
  • VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials.
  • Basal cell carcinoma is the most common cancer in the U.S. with approximately 3.6 million diagnoses annually & is generally treated with invasive surgery that carries risks of pain, infection, bleeding, & scarring.
  • Verrica's FDA-approved product YCANTH (VP-102) treats molluscum contagiosum & is in development for common warts.
  • Verrica has a worldwide license agreement with Lytix Biopharma AS to develop & commercialize VP-315 for non-melanoma skin cancers.